ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
iTeos Therapeutics Inc

iTeos Therapeutics Inc (ITOS)

13.52
0.35
( 2.66% )
Updated: 15:34:24

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
13.52
Bid
13.51
Ask
13.53
Volume
261,782
12.83 Day's Range 13.70
8.20 52 Week Range 18.24
Market Cap
Previous Close
13.17
Open
13.35
Last Trade
10
@
13.52
Last Trade Time
15:36:19
Financial Volume
$ 3,507,538
VWAP
13.3987
Average Volume (3m)
270,549
Shares Outstanding
35,843,131
Dividend Yield
-
PE Ratio
-4.31
Earnings Per Share (EPS)
-3.14
Revenue
12.6M
Net Profit
-112.64M

About iTeos Therapeutics Inc

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ITOS. The last closing price for iTeos Therapeutics was $13.17. Over the last year, iTeos Therapeutics shares have traded in a share price range of $ 8.20 to $ 18.24.

iTeos Therapeutics currently has 35,843,131 shares outstanding. The market capitalization of iTeos Therapeutics is $485.32 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -4.31.

ITOS Latest News

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 3 - Initial statement of beneficial ownership of securities

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS   Know all by these presents, that the undersigned hereby constitutes and appoints Michel Detheux, Adi Osovsky and...

Form S-8 - Securities to be offered to employees in employee benefit plans

    As filed with the Securities and Exchange Commission on March 6, 2024   Registration No. 333-     UNITED STATES   SECURITIES AND EXCHANGE...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

0001808865falseFYhttp://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember2016-05-312021-12-312021-02-282030-01-312021-11-302027-02-280001808865us-gaap:CorporateDebtSecurities...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.421.582733812911.1213.711.0434028812.21021244CS
42.5222.90909090911113.710.226612711.58735762CS
122.2720.177777777811.2513.79.727054910.92104606CS
262.0117.463075586411.5113.78.237602610.20772592CS
52-0.13-0.95238095238113.6518.248.235802811.85558769CS
156-20.83-60.640465793334.3552.438.236328821.81303035CS
260-6.18-31.370558375619.752.438.233356322.83028903CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 29.47
(520.42%)
29.37M
XLOXilio Therapeutics Inc
$ 1.22
(90.92%)
31.24M
CEROCERo Therapeutics Holdings Inc
$ 3.04
(86.50%)
21.43M
NXLNexalin Technologies Inc
$ 1.39
(78.21%)
10.6M
KYCHKeyarch Acquisition Corporation
$ 11.93
(70.30%)
173.64k
BOLDBoundless Bio Inc
 14.55
(-75.74%)
636.7k
PMECPrimech Holdings Ltd
$ 1.30
(-66.49%)
7.43M
GMDAGamida Cell Ltd
$ 0.0365
(-38.34%)
82.38M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.2202
(-32.64%)
17.7M
NKLANikola Corporation
$ 1.01
(11.10%)
149.45M
BDRXBiodexa Pharmaceuticals PLC
$ 1.45
(68.80%)
85.88M
GMDAGamida Cell Ltd
$ 0.0365
(-38.34%)
82.38M
MARAMarathon Digital Holdings Inc
$ 22.59
(2.36%)
80.42M
AKANAkanda Corporation
$ 0.128
(-22.38%)
73M

Your Recent History

Delayed Upgrade Clock